Skip to main content

Table 1 Patients’ characteristics

From: Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

Age (year)

  
 

Mean ± SD

68.5 ± 5.6

PSA at diagnosis (ng/mL)

 
 

Mean ± SD

7.2 ± 2.6

 

10 or less

144

 

10-20

25

Clinical T stage

 
 

T1c

143

 

T2a

16

 

T2b

7

 

T2c

1

 

Ne

2

Gleason score

  
 

4-6

166

 

7

2

 

Ne

1

Neoadjuvant ADT

 
 

No

125

 

Yes

42

 

Ne

2

IPSS at baseline

 
 

Mean ± SD

6.3 ± 4.0 (*)

Follow-up period (months)

 
 

Mean (range)

50 (1–85 months)

  1. SD: Standard deviation, Ne: Not evaluated.
  2. ADT: Androgen deprivation therapy.
  3. IPSS: International prostate symptom score.
  4. (*) 162 patients included.